fianlimab LAG-3
Selected indexed studies
- Targeting LAG-3: Relatlimab, Fianlimab, and ieramilimab reshape the landscape of cancer combination immunotherapy. (Pathol Res Pract, 2025) [PMID:40784086]
- Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. (J Clin Oncol, 2024) [PMID:38900987]
- What role can LAG-3-blocking antibodies play in melanoma therapy? (Expert Opin Biol Ther, 2023) [PMID:37936502]
_Worker-drafted node — pending editorial review._
Connections
fianlimab LAG-3 is a side effect of
Sources
- Targeting LAG-3: Relatlimab, Fianlimab, and ieramilimab reshape the landscape of cancer combination immunotherapy. (2025) pubmed
- Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma. (2024) pubmed
- First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies. (2024) pubmed
- What role can LAG-3-blocking antibodies play in melanoma therapy? (2023) pubmed
- Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies. (2026) pubmed
- Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements. (2024) pubmed